Kornimate/medical-research-clean huggingface dataset:
effectiveness of preoperative surgical scrubbing using clorhexidine digluconate and parachlorometaxylenol (ecp)

Conditions: Skin Diseases; Surgical Site Infection

Summary: despite the wide variety of products and antiseptic agents, no agent is ideal for every situation. the investigators would like to evaluate the difference in reducing bacterial load, using 4% chlorhexidine digluconate and 3% parachlorometaxylenol after a preoperative surgical scrubbing.

the investigators conducted a controlled, prospective, randomized study to evaluate the antiseptic effectiveness of preoperative surgical scrubbing using 4% chlorhexidine digluconate and 3% parachlorometaxylenol. samples were taken from the hands of each volunteer after a preparatory handwash, pre-surgical scrubbing, post-surgical scrubbing and 3 hours after surgical scrubbing.

Eligibility criteria:
inclusion criteria: * no systemic diseases. * healthy skin on hands, without cuts or abrasions. * short and clean fingernails. * no use of substances with antimicrobial action (e.g. medicated soaps or creams). exclusion criteria: * history of eczema. * history of psoriasis. * allergies to any of the ingredients of the solutions or contraindication to its use.

Keywords: surgical scrubbing chlorhexidine digluconate parachlorometaxylenol
tianjin gestational diabetes prevention program (tgdpp)

Conditions: Gestational Diabetes Mellitus (GDM)

Summary: a total of 1,180 women diagnosed with gestational diabetes mellitus (gdm) from 2005 to 2009 and their children have and continues to be randomly assigned to either the intervention group or the control group. a total of 83 women with prior gdm and newly diagnosed diabetes at baseline survey have the nine-month lifestyle intervention program. gdm women in the intervention group will have five consulting sessions with a dietician during the first year and two sessions during the second year. the intervention group are given detailed advice about how to achieve the five goals of the intervention. the primary aim will test whether lifestyle intervention can reduce incident type 2 diabetes (t2d) in women with prior gdm. the second aim will test gene-intervention interactions through fine-mapping established genes for glucose, ir, lipids, obesity and t2d in relation to metabolic traits for t2d in gdm women. the third aim will evaluate the effects of the nine-month lifestyle intervention program on cardiovascular risk factors in women with prior gdm and newly diagnosed diabetes. the forth aim will assess if a lifestyle intervention targeting both gdm mothers and their offspring can greatly improve offspring's cardimetablic risk (body weight, glucose and lipid metabolism).


Eligibility criteria:
inclusion criteria for mothers: 1. age 20-49 years 2. women diagnosed with gdm between 2005 and 2009. inclusion criteria for children: age 1-5 years at baseline survey. exclusion criteria: 1. age \< 20 and ≥ 50 years 2. newly diagnosed diabetes in the screening visit 3. the presence of any chronic diseases that could seriously reduce their life expectancy or their ability to participate in the trial 4. unable or unwilling to give informed consent or communicate with study staff 5. currently pregnant, or planning to become pregnant in the next four years

Keywords: gestational diabetes mellitus lifestyle intervention
glaucoma screening with artificial intelligence

Conditions: Glaucoma

Summary: this randomized clinical trial aims to compare the diagnostic performance of two ai-enabled screening strategies - rota (rnfl optical texture analysis) assessment versus optic disc photography - in detecting glaucoma within a population-based sample. secondary objectives are to (1) compare the diagnostic performance of rota ai assessment versus oct rnfl thickness assessment by ai, and rota ai assessment versus oct rnfl thickness assessment by trained graders, (2) investigate the cost-effectiveness of ai rota assessment for glaucoma screening, and (3) estimate the prevalence of glaucoma in hong kong.

glaucoma is the leading cause of irreversible blindness affecting 76 million patients worldwide in 2020. characterized by progressive degeneration of the optic nerve, early detection of disease deterioration with timely intervention is critical to prevent progressive loss in vision. in the 5th world glaucoma association consensus meeting, a diverse and representative group of glaucoma clinicians and scientists deliberated on the value and methods of glaucoma screening. whereas it has been recognized that early detection of glaucoma for treatment is beneficial to preserve the quality of vision and quality of life as glaucoma treatments are often effective, easy to use and well tolerated, the optimal screening strategy for glaucoma has not yet been determined. rota (retinal nerve fiber layer optical texture analysis) is a patented algorithm designed to detect axonal fiber bundle loss in glaucoma. unlike conventional optical coherence tomography (oct) analysis, rota uses non-linear transformation to reveal the optical textures and trajectories of axonal fiber bundles, allowing for intuitive and reliable recognition of rnfl abnormalities without the need for normative databases. it can be applied across different oct models and is particularly effective at detecting focal rnfl defects in early glaucoma and varying degrees of rnfl damage in end-stage glaucoma. the proposed study will address whether the application ai on rota is feasible and cost-effective in the setting of glaucoma screening, and whether rota would outperform optic disc photography and oct rnfl thickness assessment.

Eligibility criteria:
inclusion criteria: * individuals aged 50 years or above exclusion criteria: * physically incapacitated * not able to cooperate for clinical examination or optical coherence tomography (oct) investigation will be excluded

Keywords: ophthalmology glaucoma artificial intelligence retinal nerve fiber layer optical texture analysis optic disc photography assessment
the direct iii post market study

Conditions: Coronary Artery Disease

Summary: the primary objective of this multicenter, single-arm, observational study is to evaluate the feasibility of a systematic direct stenting strategy with the svelte slender ids sirolimus-eluting coronary stent-on-a-wire integrated delivery system (slender ids) in an all-comers, real-world population.

in this post-market study, the population will include real-world subjects who are intended to be treated, with slender ids as standard therapy. follow-up contacts post procedure will be made for clinical assessments at hospital discharge, 1, 6 and 12 months. this study is designed as a prospective, multi-center, single-arm, observational all-comers clinical study to collect ongoing safety and efficacy of slender ids and to determine the feasibility of a direct stenting strategy in an all-comers population. a minimum of two hundred fifty (250) subjects will be treated at up to 20 sites in europe. review of safety data and risks to subjects will be monitored by an independent clinical events committee (cec) at pre-specified enrollment milestones.

Eligibility criteria:
inclusion criteria: 1. subject is ≥ 18 years old; 2. subject has symptomatic heart disease due to coronary artery lesions of length \< 28 mm and a reference vessel diameter 2.5 - 4.0 mm. 3. subject is intended to be treated with pci and implantation of slender ids as part of his/her standard treatment 4. subject or subject's legal representative understands the study requirements and the treatment procedures and provides written informed consent before any study specific tests or procedures are performed. exclusion criteria: 1. subject is unable to receive anti-platelet and/or anti-coagulant therapy; 2. subject is allergic to sirolimus, pea iii ac bz, cobalt, chromium, nickel or tungsten; 3. the subject is judged to have lesions preventing complete inflation of an angioplasty balloon or proper placement of a coronary stent, including chronic total occlusions. 4. subject is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential, based on the standard of care for the cath lab); 5. subject is participating in another investigational drug or device clinical trial that the investigator feels would interfere with the subject's participation in this study.
sph5030 tablets in subjects with advanced her2-positive solid tumors

Conditions: HER2-positive Advanced Solid Tumors

Summary: to evaluate the safety and tolerability of sph5030 tablets in subjects with her2-positive advanced solid tumors


Eligibility criteria:
inclusion criteria: 1. ecog performance status of 0 to 1. 2. life expectancy of more than 3 months. 3. at least one measurable lesion exists.(recist 1.1) 4. histologically or cytologic confirmed her2 positive metastatic solid tumor which failed prior standard treatment or have no standard treatment. 5. required laboratory values including following parameters: anc: ≥ 1.5 x 109/l plt count: ≥ 90x 109/l hb: ≥ 90 g/l tbil: ≤ 1.5 x uln, alt and ast: ≤ 2.5 x uln and creatine clearance rate: uln or≥ 50 ml/min 6. toxicity from previous antitumor therapy returned to baseline (except for residual hair loss effects) or ctcae≤ class 1. 7. blood pregnancy test was negative within 3 days prior to first dose. exclusion criteria: 1. subjects who have received the prescribed treatment at the prescribed time prior to first dosing. 2. known active infection within 2 weeks prior to baseline. 3. subjects with third space fluid that can not be controled. 4. subjects with uncontrolled or severe cardiovascular disease. 5. subjects with uncontrolled hypokalemia and hypomagnesemia before study entry. 6. subjects with severe lung disease. 7. subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption. 8. using a potent cyp3a4 or cyp2c8 inhibitor or inducer. 9. steroid treatment for more than 50 days before, or in need of long-term use of steroids. 10. uncured other tumors within 5 years. 11. subjects with symptomatic cns metastasis, pia meningeal metastasis, or spinal cord compression due to metastasis. 12. evidence of chronic active hepatitis b or c 13. uncontrolled systemic diseases, including hypertension that cannot be effectively controlled after treatment. 14. receive any live or attenuated live vaccine within 28 days prior to baseline. 15. evidence of severe allergies. 16. evidence of alcohol or drug abuse. 17. evidence of neurological or psychiatric disorders.
the effect of using preendoscopic proton pump inhibitors in upper gastrointestinal system bleeding on patient prognosis

Conditions: Upper Gastrointestinal Bleeding, Proton Pump Inhibitors

Summary: in this study, we aimed to investigate the effectiveness of ppi use in upper gastrointestinal bleeding in patients over the age of 18 who underwent endoscopy on mortality, length of hospital stay, rebleeding, and cost. the european society of gastrointestinal endoscopy 2021 recommends the use of preendoscopic ppi in patients with nonvariceal upper gastrointestinal bleeding as it reduces the need for endoscopic treatment. this recommendation is recommended by the british institute for health and care excellence not to use proton pump inhibitors. likewise, the 2021 american gastroenterology association did not make a recommendation for its use because the benefit of using preendoscopic ppi is uncertain. this has led to confusion about the efficacy of ppi and has questioned the necessity of routinely given high-dose ppi therapy. in this study, we aim to reveal the effectiveness of the treatment by comparing the patients who were given and not given ppi. our research is a retrospective cohort study. patients over the age of 18 who applied to the emergency department and had a preliminary diagnosis of upper gastrointestinal bleeding and underwent endoscopy will be included in the study. patients who underwent endoscopy and were given ppi and those who were not will be compared. in upper gastrointestinal bleeding, patients with a glasgow blatchford score of 2 and above are taken to endoscopy. therefore, patients over the age of 18 who underwent endoscopy will be included in the study.

due to the problems experienced in the supply of ppi, ppi was not available in our hospital for a while. therefore, ppi could not be given to the patients. it was started to be given after the drug was re-supplied. in our study, we retrospectively analyzed patients who could and could not receive ppi. the data of the patients were as follows: age, gender, complaints on admission, known diseases, vital signs, medications used, rectal examination, whole blood parameters, biochemistry parameters, glasgow blatchford scores, endoscopy results, whether they received blood products, how much of each product they received, emergency we recorded service outcomes and emergency room costs.

Eligibility criteria:
inclusion criteria: * having an endoscopy at the time of admission to the emergency room * glasgow blatchford score of 2 or higher * be over 18 years old exclusion criteria: * patients who do not meet the inclusion criteria will be excluded
nitrate supplementation in chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: each subject will consume (in a randomized fashion) both the intervention beverage (nitrate solution) and the placebo, separated by a 1 wk washout period. the investigators will test the hypothesis that 7 days of dietary nitrate supplementation will improve metabolic efficiency in patients with copd compared to the placebo.


Eligibility criteria:
inclusion criteria: * copd * indication metabolic inefficiency exclusion criteria: * sodium intake limitation * long-term oxygen therapy * severe renal impairment * use of medications that may interact with nitrate * contra-indications for performing (sub)maximal cycle ergometry

Keywords: copd nitrate supplementation metabolic efficiency
associations among serum and gastric juice bile acid profile, bile acid-microbiota cross-talk in stomach and the development of gastric cancer

Conditions: Bile Reflux; Gastric Cancer; Precancerous Lesion

Summary: to explore the associations among bile acid profile, bile acid-microbiota cross-talk and the development of gastric cancer, so as to better prevent the occurrence and development of gastric cancer

this study is a case-control study. patients, according to the pathological results, will be consecutively enrolled and divided into gastric cancer group, gastric precancerous lesions group, and chronic gastritis group. the serum and gastric juice bile acid profiles, gastric microbial composition of each group patients will be detected.

Eligibility criteria:
inclusion criteria: 1. age 18 to 75 years old, gender is not limited; 2. no history of antibiotic or probiotic use for 8 weeks; 3. no preoperative chemotherapy or radiation therapy prior to the examination; 4. voluntary intravenous blood collection, gastroscopy, extraction of gastric juice and pathological biopsy. 5. voluntary testing for h. pylori exclusion criteria: 1. had undergone upper gastrointestinal and colon surgery; 2. previous diagnosis of malignant tumors; 3. presence of a disease or medication that affects bile acid metabolism, such as endocrine or autoimmune diseases; 4. recent use of drugs that affect gastrointestinal motility; 5. presence of contraindications to endoscopy; 6. pregnant and lactating women; 7. those with mental disorders; 8. refusal to sign the informed consent form.

Keywords: bile acid gastric microbiota gastric cancer precancerous lesion
somatosensory profiling in radicular pain patients and it's correlation with treatment outcome

Conditions: Radiculopathy; Lower Extremity Radicular Pain

Summary: the investigators hypothesize that there may exist different quantitative sensory profiles between radicular pain patients who respond and those who do not respond to the standard therapy of epidural steroid injections (esi).

the investigators are comparing warm/cold sensation, heat/cold pain threshold, heat/cold pain tolerance, wind-up, and conditioned pain modulation (cpm) as measured by quantitative sensory testing (qst) between subjects with a radicular pain condition. the investigators are comparing those who respond and those who do not respond to standard therapy (esi) before and after the treatment.

Eligibility criteria:
inclusion criteria: * diagnosis of lower extremity radicular pain regardless of specific or suspected etiologies * scheduling an epidural steroid injection (esi) exclusion criteria: * a major psychiatric disorder requiring a recent (within one month) hospitalization, such as major depression, bipolar disorder, schizophrenia, anxiety disorder, and psychosis * subject is taking illicit or recreational drug detected through a urine toxicology screen * subject has had an interventional pain management procedures within the last eight weeks that may alter qst responses including neuraxial or local anesthetic block * subject had a change in dosage of neuromodulatory pain medication (including gabapentin, pregabalin, cymbalta, amitriptyline, nortriptyline, trileptal, etc) in the past two weeks * subject is pregnant * subject has pending litigation involving the current pain condition being treated and studied.

Keywords: radicular pain epidural steroid injection
can the thoracic replace the conventional radiography for the diagnosis of acute pneumonia in children?

Conditions: Pneumonia

Summary: the thoracic ultrasound is a safer and sensitive technique than conventional radiography because it detects less than 1 cm pneumonic consolidations and minimal pleural effusions. the main objective is to evaluate the efficacy of thoracic ultrasound performed by unskilled personnel in the emergency service prdiatricas to diagnose pneumonia in children.

diagnostic test evaluation.the sample collected sequentially until an exact size . given the safety of the technique, which involves no risk to patient management and the possibility of generating a type ii error by premature study discontinuation , we have no plans to make any interim analyzes .

Eligibility criteria:
inclusion criteria: * fever above 38 degrees * tachypnea * difficulty breathing * side tip pain * pathological auscultation exclusion criteria: * \ 14 years * background of prematurity * rewalizados imaging studies in the last 7 days * any chronic respiratory process * congenital heart diseases * hemodynamic instability * diagnosis of pneumonia in the last 3 months * refusal of relatives to participate in the study

Keywords: thoracic ultrasound children efficacy emergency service
administration for placebo group and evalution the safety and efficacy in atopic dermatitis patients

Conditions: Atopic Dermatitis

Summary: a multi-center, open, single-arm clinical trial to evaluate the safety and efficacy of furestem-ad inj. in patients with moderate to severe chronic atopic dermatitis who participated in a placebo group in k0102 clinical trial: 2nd extension study of k0102


Eligibility criteria:
inclusion criteria: 1. subject who enrolled k0102 clinical trial(parent study) and be assigned to a placebo group 2. subjects who understand and voluntarily sign an informed consent form exclusion criteria: 1. subjects with medical history or surgery/procedure history 2. subjects with diseases at the time of participation in this study (systemic infection, other serious skin disorders, pigmentation or extensive scarring in atopic dermatitis symptom region) 3. pregnant, breast-feeding women or women who plan to become pregnant during six months after administering the clinical trial medication 4. subjects who participate in other clinical trial or participated in other clinical trial within 4 weeks 5. in case follow-up is not possible to end of this study period 6. any other condition which the investigator judges would make patient unsuitable for study participation
greater occipital nerve injection study

Conditions: Occipital Neuralgia; Cervicogenic Headache

Summary: this study is designed to answer the question of whether injection of the greater occipital nerve at its proximal origin, near the c2 vertebrae, using ultrasound guidance is effective in improving pain in human subjects. hypotheses 1. ultrasound (us) guided greater occipital nerve (gon) injections are effective at a novel, proximal c2 location in live, human subjects, measured by improvement in visual analog scale (vas) pain scores pre-injection compared to vas scores 30 minutes post-injection, 2-weeks post-injection, and 1-month post-injection . 2. ultrasound (us) guided injection of the greater occipital nerve (gon) at a novel, c2 location is effective at improvement of both occipital neuralgia and cervicogenic headache demonstrated by improvement in visual analog scale (vas) pain scores pre-injection compared to vas scores 30 minutes post-injection, 2-weeks post-injection, and 1-month post-injection. we further hypothesize that the mean improvement in vas scores at 1-month post injection will be greater than 2 units. 3. ultrasound (us) guided injection of the greater occipital nerve (gon) at novel, proximal c2 location in live, human subjects appears safe.

patients must be referred to pain clinic for occipital nerve injection. patients are responsible for all clinical costs associated with the injection. there is no remuneration offered for participation in this study.

Eligibility criteria:
inclusion criteria: subjects must be referred to the pain clinic for an occipital nerve injection. * must have occipital neuralgia and/or cervicogenic headache exclusion criteria: * bilateral gon symptoms and/or cervicogenic headache symptoms * history of cervical spine surgery/procedure or trauma in past 6 months that may have caused or contributed to the occipital pain or cervicogenic headache, excluding occipital nerve blocks (onb). * evidence of impaired sensation in the gon dermatome region * evidence of cranial defect/abnormality near target injection site * untreated cutaneous infection, systemic illness, or immunocompromised state * history of bleeding tendency or use of anticoagulants * history of adverse reaction to anesthetic agents or corticosteroids * occipital nerve block in past 3 months

Keywords: greater occipital nerve occipital neuralgia cervicogenic headache
ed adaptive staffing study

Conditions: Emergency Medicine; Well-Being, Psychological

Summary: emergency departments (eds) across ontario are being inundated with unprecedented high patient volumes and a staffing shortage that directly impacts patient care and flow. an area of concern among eds is the offload zone where patients are brought in by ambulance. ems offload time is the time it takes paramedics to transfer a patient to the appropriate area within an emergency department and give hospital staff a summary of what concerns the patient is seeking care for. there are multiple factors that may delay this time, including limited staff in the offload area to complete the transfer process due to competing patient care responsibilities. the adaptive staffing model study will look to add a primary care paramedic (pcp) or a registered nurse (rn) in the offload zone during times of high ambulance volume (august to january) to help with patient care within the offload zone. this single-centered community hospital study will evaluate the benefits of having a pcp or rn, compared to the current model, on ambulance offload times, patient safety outcomes, patient treatment times, and staff well-being using three different models of staffing.


Eligibility criteria:
inclusion criteria: * patients brought in by ambulance to hospitals emergency department offload area exclusion criteria: * patients not arriving to the hospitals emergency department offload area